Business Context and Reporting Period
This Form 6-K filing by GSK plc, dated September 14, 2026, reports on the month of September 2026. The filing announces positive overall survival (OS) data from the ARTEMIS-008 pivotal Phase III trial conducted in China. The trial evaluates risvutatug rezetecan (Ris-Rez), a B7-H3-targeted antibody-drug conjugate (ADC), versus topotecan in patients with relapsed small cell lung cancer (SCLC). GSK holds exclusive rights to develop and commercialize Ris-Rez outside mainland China, Hong Kong, Macau, and Taiwan.
Key Financial and Clinical Metrics
The filing does not provide financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. It focuses exclusively on clinical trial outcomes. Key clinical metrics from the ARTEMIS-008 trial include:
- Overall Survival (OS): Ris-Rez reduced the risk of death by 54% compared to topotecan (Hazard Ratio 0.46; p<0.0001).
- Median OS: 18.5 months for Ris-Rez versus 10.3 months for topotecan.
- Progression-Free Survival (PFS): Median PFS was 7.2 months for Ris-Rez versus 3.0 months for topotecan (HR 0.33).
- Objective Response Rate (ORR): 58.3% for Ris-Rez versus 12.6% for topotecan.
- Disease Control Rate: 90.4% for Ris-Rez versus 60.2% for topotecan.
- Safety: Grade 3 or higher treatment-related adverse events occurred in 60.9% of Ris-Rez patients versus 78.2% of topotecan patients.
Material Changes and Developments
The primary material development is the confirmation of a statistically significant and clinically meaningful improvement in overall survival for Ris-Rez in relapsed SCLC. This represents the first Phase III data to demonstrate an OS benefit for a B7-H3 ADC in any tumor type. The results were presented at the 2026 World Conference on Lung Cancer (WCLC) in Seoul, South Korea. These findings support the expansion of GSK's global development program for Ris-Rez across later-line and earlier treatment settings for SCLC, as well as other solid tumors.
Guidance, Outlook, and Risks
Outlook and Management Commentary: GSK management views these results as a significant step forward for its lung cancer portfolio, providing momentum for global development. The company is advancing a broad clinical program, including the Phase III EMBOLD SCLC-301 trial in relapsed extensive-stage SCLC, with pivotal data expected in the following year. GSK aims to develop Ris-Rez across more than 40 indications by 2040.
Risks and Contingencies: The filing includes a cautionary statement regarding forward-looking statements, noting that actual results may differ materially due to risks described in GSK's 2025 Annual Report on Form 20-F and Q2 2026 results. Specific risks include the uncertainties inherent in clinical development and regulatory approvals.
Key Facts for Investor Verification
- Verify the regulatory status and approval timeline for Ris-Rez in markets outside China, given GSK's exclusive rights in those regions.
- Monitor the upcoming pivotal data from the Phase III EMBOLD SCLC-301 trial expected in the next year.
- Assess the commercial potential of Ris-Rez in the context of the current standard of care for relapsed SCLC, where median survival is approximately 12-13 months.
- Review the safety profile of Ris-Rez in broader populations, noting that hematologic adverse events were the most common severe side effects.
- Confirm the impact of these clinical results on GSK's overall oncology pipeline valuation and potential future revenue streams.